STING1 and malignant colon neoplasm: Furthermore, in combination with the SHP2 agonist lovastatin and ATR inhibitors, PARP1 can activate the cGAS-STING pathway and play an antitumor role in colon cancer and PBRM1-deficient renal clear cell carcinoma (120, 121).